FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy.

BRCAness revisited. Nat Rev Cancer (2016) 1.38

Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. Gynecol Oncol (2015) 0.91

ATM Kinase Is Required for Telomere Elongation in Mouse and Human Cells. Cell Rep (2015) 0.85

New treatment option for ovarian cancer: PARP inhibitors. Gynecol Oncol Res Pract (2016) 0.80

Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies. Oncotarget (2017) 0.78

PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression. Clin Cancer Res (2017) 0.78

Identification of small molecule inhibitors of ERCC1-XPF that inhibit DNA repair and potentiate cisplatin efficacy in cancer cells. Oncotarget (2016) 0.78

Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer. Oncotarget (2016) 0.77

Characterization of a novel germline PALB2 duplication in a hereditary breast and ovarian cancer family. Breast Cancer Res Treat (2016) 0.77

Successes and Challenges of PARP Inhibitors in Cancer Therapy. Front Oncol (2015) 0.77

A small molecule inhibitor of WEE1, AZD1775, synergizes with olaparib by impairing homologous recombination and enhancing DNA damage and apoptosis in acute leukemia. Mol Cancer Ther (2017) 0.76

Cancer's Achilles' Heel: Apoptosis and Necroptosis to the Rescue. Int J Mol Sci (2016) 0.76

Apoptosis is augmented in high-grade serous ovarian cancer by the combined inhibition of Bcl-2/Bcl-xL and PARP. Int J Oncol (2017) 0.75

Exome Sequencing Identifies Potentially Druggable Mutations in Nasopharyngeal Carcinoma. Sci Rep (2017) 0.75

A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial. Trials (2016) 0.75

Oleandrin induces DNA damage responses in cancer cells by suppressing the expression of Rad51. Oncotarget (2016) 0.75

Linking DNA Damage and Hormone Signaling Pathways in Cancer. Trends Endocrinol Metab (2016) 0.75

Let-7 Status is Crucial for PARP1 Expression in HER2-overexpressing Breast Tumors. Mol Cancer Res (2016) 0.75

Emerging therapies for breast cancer. J Hematol Oncol (2017) 0.75

Novel PARP-1 Inhibitor Scaffolds Disclosed by a Dynamic Structure-Based Pharmacophore Approach. PLoS One (2017) 0.75

Reciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2. Oncotarget (2016) 0.75

Mesothelium expression of vascular cell adhesion molecule-1 (VCAM-1) is associated with an unfavorable prognosis in epithelial ovarian cancer (EOC). Cancer (2016) 0.75

ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells. Genes Dev (2017) 0.75

The synthetic lethal killing of RAD54B-deficient colorectal cancer cells by PARP1 inhibition is enhanced with SOD1 inhibition. Oncotarget (2016) 0.75

Fluorescent sensors of PARP-1 structural dynamics and allosteric regulation in response to DNA damage. Nucleic Acids Res (2016) 0.75

Drugging the Cancers Addicted to DNA Repair. J Natl Cancer Inst (2017) 0.75

Systems analysis of dynamic transcription factor activity identifies targets for treatment in olaparib resistant cancer cells. Biotechnol Bioeng (2017) 0.75

Recent advances in targeting DNA repair pathways for the treatment of ovarian cancer and their clinical relevance. Int J Clin Oncol (2017) 0.75

Synthetic lethality between the cohesin subunits STAG1 and STAG2 in diverse cancer contexts. Elife (2017) 0.75

A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells. BMC Cancer (2017) 0.75

New roles for Dicer in the nucleolus and its relevance to cancer. Cell Cycle (2017) 0.75

Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions. Curr Med Chem (2016) 0.75

PARP inhibitors: Clinical utility and possibilities of overcoming resistance. Gynecol Oncol (2017) 0.75

Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer. Clin Cancer Res (2017) 0.75

Safe handling of oral antineoplastic medications: Focus on targeted therapeutics in the home setting. J Oncol Pharm Pract (2016) 0.75

FDA Approval Summary: Ramucirumab for Gastric Cancer. Clin Cancer Res (2015) 0.90